Does Rallies show 13F holders for BNTX?

Yes. Rallies tracks hedge fund and 13F ownership data for BNTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BNTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BNTX. It does not provide personalized investment advice.

BNTX (BioNTech) Stock Analysis - Hedge Fund Holdings

BioNTech (BNTX) is a publicly traded Healthcare sector company. As of May 20, 2026, BNTX trades at $90.36 with a market cap of $22.47B and a P/E ratio of 0.00. BNTX moved +2.64% today. Year to date, BNTX is -9.20%; over the trailing twelve months it is -10.24%. Its 52-week range spans $79.52 to $129.27. Analyst consensus is strong buy with an average price target of $136.36. Rallies surfaces BNTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BNTX stock?

Hedge funds tracked by Rallies that own BNTX include Temasek Holdings, Viking Global, Centerbook Partners, Orbimed Advisors, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioNTech.

BNTX Key Metrics

Key financial metrics for BNTX
Metric	Value
Price	$90.36
Market Cap	$22.47B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	2.13%
52-Week High	$129.27
52-Week Low	$79.52
Volume	760.76K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding BNTX

Temasek Holdings holds 1.51M shares of BNTX, changed +0.00% as of Mar 31, 2026.
Viking Global holds 879.97K shares of BNTX, changed -6.47% as of Mar 31, 2025.
Centerbook Partners holds 171.17K shares of BNTX, changed -27.53% as of Mar 31, 2026.
Orbimed Advisors holds 103.00K shares of BNTX, changed +0.00% as of Sep 30, 2024.
Redmile Group holds 73.07K shares of BNTX, changed -12.46% as of Mar 31, 2025.

Latest BNTX News

BioNTech Expands Supervisory Board to Eight, Adds Two Oncology Experts — May 15, 2026
BioNTech authorizes new $1 billion ADS buyback program through May 2027 — May 7, 2026
BioNTech Authorizes $1 Billion ADS Repurchase Program Through May 2027 — May 7, 2026
BioNTech drops as Q1 revenue falls, losses widen despite $1B buyback — May 6, 2026
BioNTech slides as Q1 revenue miss and wider loss outweigh planned $1B buyback — May 5, 2026

Recent BNTX Insider Trades

Poetting Sierk sold 50.00K (~$5.53M) on Apr 22, 2026.

BNTX Analyst Consensus

15 analysts cover BNTX: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $136.36.

Common questions about BNTX

Who owns BNTX stock?: Hedge funds tracked by Rallies that own BNTX include Temasek Holdings, Viking Global, Centerbook Partners, Orbimed Advisors, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioNTech.
Does Rallies show 13F holders for BNTX?: Yes. Rallies tracks hedge fund and 13F ownership data for BNTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BNTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BNTX. It does not provide personalized investment advice.